Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PPOX | P50336 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707979 | 0.84 | MAPT (0.60) | MAPTTDP1KDM4EKMT2AMEN1 | |
| SCHEMBL21707908 | 0.83 | TSHR (0.48) | MAPTTDP1KDM4EKMT2AMEN1 | |
| SCHEMBL21707869 | 0.78 | MAPT (0.58) | MAPTTDP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL21707983 | 0.77 | ALDH1A1 (0.49) | MAPTTDP1KDM4EKMT2AMEN1 | |
| SCHEMBL14333492 | 0.76 | CYP1A2 (0.47) | MAPTSNCAKDM4EKMT2AMEN1 | |
| SCHEMBL268658 | 0.76 | TDP1 (0.55) | MAPTTDP1KDM4EKMT2AMEN1 | |
| SCHEMBL4255397 | 0.76 | TDP1 (0.55) | MAPTTDP1KMT2AALDH1A1LMNA | |
| SCHEMBL14333508 | 0.76 | MAPT (0.64) | MAPTKDM4EKMT2AMEN1HTT | |
| SCHEMBL5105312 | 0.75 | POLB (0.52) | MAPTKMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL8787027 | 0.75 | CYP3A4 (0.48) | MAPTTDP1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | SLC2A3, SLC2A4, SLC2A1 | MAPT 1704/4885SNCA 4256/4885TDP1 4032/4885 |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | SLC2A3, SLC2A4, SLC2A1 | MAPT 1704/4885SNCA 4256/4885TDP1 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.